Lesson plan

Danicopan

Danicopan, sold under the brand name Voydeya, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria. It is a complement inhibitor which reversibly binds to factor D to prevent alternative pathway-mediated hemolysis and deposition of complement C3 proteins on red blood cells. The most common side effects include fever, headache, increased levels of liver enzymes and pain in the extremities. Danicopan was approved for medical use in Japan in January 2024, in the United States in March 2024, and in the European Union in April 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Back to article

Article summary

Danicopan, sold under the brand name Voydeya, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria. It is a complement inhibitor which reversibly binds to factor D to prevent alternative pathway-mediated hemolysis and deposition of complement C3 proteins on red blood cells. The most common side effects include fever, headache, increased levels of liver enzymes and pain in the extremities. Danicopan was approved for medical use in Japan in January 2024, in the United States in March 2024, and in the European Union in April 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.